Literature DB >> 26951252

What Causes Lupus Flares?

David Fernandez1, Kyriakos A Kirou2.   

Abstract

Systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease, follows a chronic disease course, punctuated by flares. Disease flares often occur without apparent cause, perhaps from progressive inherent buildup of autoimmunity. However, there is evidence that certain environmental factors may trigger the disease. These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms. Uncontrolled disease flares, as well as their treatment, especially with glucocorticoids, can cause significant organ damage. Tight surveillance and timely control of lupus flares with judicial use of effective treatments to adequately suppress the excessive immune system activation are required to bring about long term remission of the disease. We hope that new clinical trials will soon offer additional effective and target-specific biologic treatments for SLE.

Entities:  

Keywords:  Drugs; Flare; Hormones; Infections; Systemic lupus erythematosus; Triggers

Mesh:

Substances:

Year:  2016        PMID: 26951252     DOI: 10.1007/s11926-016-0562-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  95 in total

1.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Authors:  William Stohl; Falk Hiepe; Kevin M Latinis; Mathew Thomas; Morton A Scheinberg; Ann Clarke; Cynthia Aranow; Frank R Wellborne; Carlos Abud-Mendoza; Douglas R Hough; Lilia Pineda; Thi-Sau Migone; Z John Zhong; William W Freimuth; W Winn Chatham
Journal:  Arthritis Rheum       Date:  2012-07

2.  Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus.

Authors:  Stephan Meller; Franziska Winterberg; Michel Gilliet; Anja Müller; Ingrida Lauceviciute; Juliane Rieker; Norbert J Neumann; Robert Kubitza; Michael Gombert; Erich Bünemann; Ulrike Wiesner; Petra Franken-Kunkel; Holger Kanzler; Marie-Caroline Dieu-Nosjean; Ali Amara; Thomas Ruzicka; Percy Lehmann; Albert Zlotnik; Bernhard Homey
Journal:  Arthritis Rheum       Date:  2005-05

3.  Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study.

Authors:  Annegret Kuhn; Kristina Gensch; Merle Haust; Anna-Maria Meuth; France Boyer; Patrick Dupuy; Percy Lehmann; Dieter Metze; Thomas Ruzicka
Journal:  J Am Acad Dermatol       Date:  2011-01       Impact factor: 11.527

4.  A trial of contraceptive methods in women with systemic lupus erythematosus.

Authors:  Jorge Sánchez-Guerrero; América G Uribe; Luisa Jiménez-Santana; Marilú Mestanza-Peralta; Pilar Lara-Reyes; Armando H Seuc; María-del-Carmen Cravioto
Journal:  N Engl J Med       Date:  2005-12-15       Impact factor: 91.245

5.  Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C.

Authors:  Vincent Ho; Anna Mclean; Shaughan Terry
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

6.  How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.

Authors:  Aikaterini Thanou; Eliza Chakravarty; Judith A James; Joan T Merrill
Journal:  Rheumatology (Oxford)       Date:  2014-04-11       Impact factor: 7.580

7.  Clinical characteristics and therapy exploration of active human cytomegalovirus infection in 105 lupus patients.

Authors:  J Zhang; Y Dou; Z Zhong; J Su; D Xu; F Tang; X Zhang; Y Zhao; X Zeng; F Zhang; X You
Journal:  Lupus       Date:  2014-05-16       Impact factor: 2.911

8.  T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.

Authors:  Eoin F McKinney; James C Lee; David R W Jayne; Paul A Lyons; Kenneth G C Smith
Journal:  Nature       Date:  2015-06-29       Impact factor: 49.962

9.  Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

Authors:  David Isenberg; Caroline Gordon; Daiana Licu; Samuel Copt; Claudia Pena Rossi; David Wofsy
Journal:  Ann Rheum Dis       Date:  2014-06-20       Impact factor: 19.103

Review 10.  Pathophysiology of cutaneous lupus erythematosus.

Authors:  Jordan C Achtman; Victoria P Werth
Journal:  Arthritis Res Ther       Date:  2015-08-10       Impact factor: 5.156

View more
  16 in total

Review 1.  A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.

Authors:  Anca D Askanase; Richard A Furie
Journal:  Adv Ther       Date:  2022-05-31       Impact factor: 4.070

2.  Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.

Authors:  Anniek Zaalberg; Sara Moradi Tuchayi; Amir H Ameri; Kenneth H Ngo; Trevor J Cunningham; Jean-Pierre Eliane; Maia Livneh; Thomas D Horn; Ilana S Rosman; Amy Musiek; Milan J Anadkat; Shadmehr Demehri
Journal:  J Invest Dermatol       Date:  2018-07-17       Impact factor: 8.551

Review 3.  Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.

Authors:  Marilyn E Allen; Violeta Rus; Gregory L Szeto
Journal:  Trends Mol Med       Date:  2020-10-09       Impact factor: 11.951

Review 4.  Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.

Authors:  Aikaterini Thanou; Eldon Jupe; Mohan Purushothaman; Timothy B Niewold; Melissa E Munroe
Journal:  J Autoimmun       Date:  2021-02-22       Impact factor: 7.094

5.  Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.

Authors:  Richard A Furie; Daniel J Wallace; Cynthia Aranow; James Fettiplace; Barbara Wilson; Prafull Mistry; David A Roth; David Gordon
Journal:  Arthritis Rheumatol       Date:  2018-04-25       Impact factor: 10.995

Review 6.  Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction.

Authors:  Hamdy Ma Ahmed; Samar Abohamad; Mohanad Elfishawi; Mohamed Tharwat Hegazy; Kadambari Vijaykumar
Journal:  Patient Prefer Adherence       Date:  2018-11-21       Impact factor: 2.711

Review 7.  Intimate Relations-Mitochondria and Ageing.

Authors:  Michael Webb; Dionisia P Sideris
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

Review 8.  A Case of Systemic Lupus Erythematosus Flare Triggered by Severe Coronavirus Disease 2019.

Authors:  Sairam Raghavan; Sriram Gonakoti; Iriagbonse Rotimi Asemota; Benjamin Mba
Journal:  J Clin Rheumatol       Date:  2020-09       Impact factor: 3.517

9.  Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?

Authors:  Erika Aurora Martínez-García; Maria Guadalupe Zavala-Cerna; Andrea Verónica Lujano-Benítez; Pedro Ernesto Sánchez-Hernández; Beatriz Teresita Martín-Márquez; Flavio Sandoval-García; Mónica Vázquez-Del Mercado
Journal:  Front Immunol       Date:  2018-07-06       Impact factor: 7.561

10.  Differential parameters between activity flare and acute infection in pediatric patients with systemic lupus erythematosus.

Authors:  Kai-Ling Luo; Yao-Hsu Yang; Yu-Tsan Lin; Ya-Chiao Hu; Hsin-Hui Yu; Li-Chieh Wang; Bor-Luen Chiang; Jyh-Hong Lee
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.